Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 Capsule in Non-segmental Vitiligo (Phase II)
CTR20254645Phase 2Active
- Sponsor
- Hangzhou Yuhong Pharmaceutical Technology
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YH001 in Vitiligo (4 arms), sponsored by Hangzhou Yuhong Pharmaceutical Technology. Primary endpoint: Percent change from baseline in facial Vitiligo Area Scoring Index (F-VASI). Started Nov 2025; status: active.
02
Drugs
YH001
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20254645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254645.